Cancer Medicine · global
Postoperative Colorectal Cancer Surveillance: Whole-Genome Oncodetect Achieves 72.2% Sensitivity for Recurrence Detection
With a single postoperative blood draw, the whole-genome version detects more trace tumor DNA signals. But after identifying patients at high risk of recurrence, determining how to adjust treatment to improve outcomes remains the next hurdle.
Even after surgery removes the visible tumor, patients may still face a difficult question: have enough cancer cells remained in the body to cause a recurrence? A colorectal cancer study announced by Abbott on October 23 showed that the whole-genome sequencing version of the Oncodetect blood test was better than the whole-exome sequencing version at identifying postoperative tumor DNA signals in patients who later experienced recurrence, providing an additional clue for risk assessment.
The β-CORRECT study analyzed postoperative samples from 279 patients, primarily those with stage II or III disease, while also including patients with resectable stage IV disease. According to the company, with a single blood draw approximately one month after surgery, sensitivity for detecting recurrence within two years was 72.2% for the whole-genome version and 42.2% for the whole-exome version, a difference of 30 percentage points. This improvement describes detection performance; it does not mean that recurrence rates declined.
Oncodetect uses a test tailored to the characteristics of each patient's tumor to track circulating tumor DNA (ctDNA) in the blood and look for signs of molecular residual disease (MRD). The whole-genome version can track up to 5,000 DNA variants specific to each patient's tumor, expanding the search to increase the chances of capturing weak signals. Among 157 patients tested with both versions, the new version detected all 29 patients who tested positive with the older version and identified 15 additional patients; all of the additional signals were below 20 parts per million.
These signals were also associated with the subsequent course of disease. The company reported that patients who were ctDNA-positive after surgery had 10.6 times the recurrence risk of those who were negative; their two-year disease-free survival rates were 36.2% and 92.3%, respectively. The difference between the groups supports the test's prognostic value, but also reminds readers that a positive result does not mean recurrence is inevitable, and a negative result cannot guarantee that the disease will not return.
The study was presented as poster 4426P at the 2026 European Society for Medical Oncology (ESMO) Congress. A separate announcement from Japan's National Cancer Center Hospital East also listed this whole-genome MAESTRO MRD validation study, confirming that Naoyoshi Hashimoto of the Department of Gastrointestinal Oncology presented it on October 23. However, the detailed performance figures currently available for verification come primarily from the company's announcement; the hospital's program confirms the presentation details.
The test's regulatory status also requires a clear distinction. Clinical Lab Products reported that Oncodetect has not received approval or clearance from the U.S. Food and Drug Administration (FDA), and that clinical testing is performed by the CLIA-certified Genomic Health laboratory. Laboratory certification and FDA review of a test product represent different levels of oversight.
A more sensitive test brings some previously difficult-to-detect postoperative signals to light; translating that information into patient benefit still requires treatment studies. The existing results have not demonstrated that increasing, reducing, or changing adjuvant treatment based on test results improves survival. Further follow-up and serial blood draws at multiple time points will help clarify the relationships among residual disease, treatment, and recurrence.